Skip to Content
Merck
  • Therapeutic effects of anodal transcranial direct current stimulation in a rat model of ADHD.

Therapeutic effects of anodal transcranial direct current stimulation in a rat model of ADHD.

eLife (2020-09-22)
Da Hee Jung, Sung Min Ahn, Malk Eun Pak, Hong Ju Lee, Young Jin Jung, Ki Bong Kim, Yong-Il Shin, Hwa Kyoung Shin, Byung Tae Choi
ABSTRACT

Most therapeutic candidates for treating attention-deficit hyperactivity disorder (ADHD) have focused on modulating the dopaminergic neurotransmission system with neurotrophic factors. Regulation of this system by transcranial direct current stimulation (tDCS) could contribute to the recovery of cognitive symptoms observed in patients with ADHD. Here, male spontaneously hypertensive rats (SHR) were subjected to consecutive high-definition tDCS (HD-tDCS) (20 min, 50 μA, current density 63.7 A/m2, charge density 76.4 kC/m2) over the prefrontal cortex. This treatment alleviated cognitive deficits, with an increase in tyrosine hydroxylase and vesicular monoamine transporter two and significantly decreased plasma membrane reuptake transporter (DAT). HD-tDCS application increased the expression of several neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF), and activated hippocampal neurogenesis. Our results suggest that anodal HD-tDCS over the prefrontal cortex may ameliorate cognitive dysfunction via regulation of DAT and BDNF in the mesocorticolimbic dopaminergic pathways, and therefore represents a potential adjuvant therapy for ADHD.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Dopamine Transporter Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Anti-NeuN Antibody (rabbit), from rabbit, purified by affinity chromatography